Evotec SESTU:EVT +1.29%61 EBITDA Margin % is -76.35% as of Mar. 2026. GuruFocus rates STU:EVT with a GF Score™ of 61/100 and a GF Value™ of €7.54 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 955 Drug Manufacturers companies, Evotec SE ranks worse than 85.03% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Evotec SE's EBITDA for the
three
months ended in Mar. 2026 was €-119.6 Mil. Evotec SE's Revenue for the
three
months ended in Mar. 2026 was €156.6 Mil. Therefore, Evotec SE's EBITDA margin for the quarter that ended in Mar. 2026 was -76.35%.
Evotec SE (STU:EVT) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Evotec SE EBITDA Margin % Related Terms
Evotec SE EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Evotec SE's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:EVT vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evotec SE EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evotec SE's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Evotec SE's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evotec SE (STU:EVT) has a EBITDA Margin % of -76.35% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Evotec SE and its competitors. According to the industry distribution chart, Evotec SE ranks #812 out of 955 companies in the Drug Manufacturers industry, placing it in the top 85%.
Is Evotec SE's EBITDA Margin % too high?
Evotec SE's current EBITDA Margin % is -76.35%. Based on the distribution chart, Evotec SE ranks #812 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Evotec SE has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Evotec SE ranks #812 out of 955 companies for EBITDA Margin %. This places Evotec SE in the lower half of its industry. The industry median EBITDA Margin % is 12.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Evotec SE and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evotec SE's current EBITDA Margin % is -76.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Based on GuruFocus' analysis, Evotec SE (STU:EVT) is currently considered Possible Value Trap. The stock's GF Value™ is €7.54, compared to a current price of €4.85 — trading 35.6% below its estimated fair value. The current EBITDA Margin % is -76.35%. Evotec SE's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Evotec SE (STU:EVT), the current EBITDA Margin % is -76.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evotec SE (STU:EVT) Overvalued in 2026?
Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued.
The current stock price of €4.85 is trading 35.6% below its estimated GF Value™ of €7.54.
GuruFocus considers Evotec SE to be Possible Value Trap.
Key valuation signals for STU:EVT:
EBITDA Margin %: -76.35%
GF Value™: €7.54 vs. price of €4.85 (35.6% below fair value)
No single metric tells the full story. See the STU:EVT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
61GF Score
Get the complete analysis for STU:EVT
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:EVT has been successfully added to your 
